Combined Blockade of Several Signalling Pathways Shows Marked Anti-Tumor Potential in Two Novel Mouse Phaeochromocytoma Cell Lines Abstract #387

Introduction: The current study explores novel targeted therapies for malignant pheochromocytomas (PCCs) and paragangliomas, utilizing a more benign (MPC) and a more malignant (MTT) PCC cell line. We have previously shown that the dual PI3K/mTORC1 inhibitor NVP-BEZ235 significantly reduced MPC and MTT cell viability, but increased ERK signalling.
Aim(s): We have now investigated the combination of NVP-BEZ235 with the established agent lovastatin, as this has been described to inhibit ERK signalling.
Materials and methods: Both cell lines, generated from heterozygous Neurofibromin 1 knock-out-mice, were treated with varying doses of lovastatin, NVP-BEZ235, or the combination of lovastatin and NVP-BEZ235, for different time periods. Metabolic viability was assessed by cell proliferation assay (MTS). Protein levels of phospho-(p) and total AKT, ERK and p70S6K were assessed by Western blotting in MPC cells.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Svenja Noelting

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...
#3320 TGF-β increase caspase activation and migration in typical bronchial carcinoids
Introduction: Typical bronchial carcinoids (TBC) are well-differentiated neuroendocrine neoplasms (NEN) whose management can still be very challenging due to reduced sensitivity to therapy. Previous studies have reported TGF-β’s ability to activate mTOR pathway and induce epithelial to mesenchymal transition (EMT). Moreover, preliminary results show an overexpression of TGF-β signalling and caspase activation in TBC.
Conference: 18th Annual ENETS Conference 2021 (2021)
Category: Basic science - Signalling pathways, receptors, biomarkers
Presenting Author: Patricia Borges de Souza
#3004 Development of Anti-SSTR CAR T Cells for Future Treatment of NETs
Introduction: NETs overexpress somatostatin receptors (SSTRs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Dr. Mauro Cives
#2800 Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells
Introduction: The most commonly used NET marker chromogranin A, has a sensitivity between 60-90% and a specificity of less than 50%, hence better NET markers are needed. Previous secretome analysis using BON1, NCI-H727 and SHP-77 cell lines has led to the discovery of various candidate NET markers. One such marker is Thymosin Beta 4 (TB4). TB4 is a small 43 amino acid intracellular peptide first isolated from bovine thymus tissue.TB4 or its oxidised form TB4SO are thought to play a role in various aspects of cancer biology including tumour invasion, metastasis and apoptosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ponni Balasundaram
#38 Expression of mTOR signaling pathway and effects of mTOR inhibitors on its pathway in human neuroendocrine tumors
Introduction: Neuroendocrine tumors (NET), especially well-differentiated endocrine tumors, are often slow-growing, indolent, and may not become clinically apparent until the manifestations of metastatic spread or carcinoid syndrome. Results of previous studies demonstrated that phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway may be activated in the great majority of NET cells. mTOR inhibitors are therefore considered effective anti-tumor reagents but they may also induce an activation of PI3K/Akt and MAPK pathways as a compensatory action and reduce their own anti-tumor activities.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Professor Hironobu Sasano
Authors: Iida S, Miki Y, Ono K, Sasano H, ...